A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain

Study Summary

The purpose of this study is to understand the incidence of transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS) and describing real-world first-line treatment patterns, healthcare resource utilization, and associated clinical outcomes in adult patients with TD LR-MDS in Spain

Conditions

Lower-risk Myelodysplastic Syndromes (TD LR-MDS)

Interventions / Drugs

Erythropoiesis-stimulating agents (ESAs)Luspatercept Lenalidomide Hypomethylating agents (HMAs)Reb blood cell transfusion

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment1300 participants

Primary Completion—

Lead SponsorBristol-Myers Squibb

Data Retrieved2026-04-11 04:08:14.746851+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.